TY - JOUR
T1 - Outcome of stem cell transplantation for Waldenström’s macroglobulinemia
T2 - analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group
AU - Sakurai, Masatoshi
AU - Mori, Takehiko
AU - Uchiyama, Hitoji
AU - Ago, Hiroatsu
AU - Iwato, Koji
AU - Eto, Tetsuya
AU - Iwasaki, Hiromi
AU - Kawata, Takahito
AU - Takamatsu, Hiroyuki
AU - Yamasaki, Satoshi
AU - Takanashi, Minoko
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Suzuki, Ritsuro
N1 - Funding Information:
The authors would like to thank all the physicians and data managers of each transplant center and all the members of the data management committees of the Japanese Data Center for Hematopoietic Cell Transplantation. This study was supported by The Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) of the Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - The role of stem cell transplantation (SCT) for patients with Waldenström’s macroglobulinemia (WM) remains undetermined. Therefore, we retrospectively evaluated the outcome of autologous and allogeneic SCT for patients with WM using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-six patients receiving autologous and 31 receiving allogeneic SCT were analyzed. The allogeneic SCT group included more patients with advanced disease status at transplant and received more lines of chemotherapy. The cumulative incidences of non-relapse mortality (NRM) at 1 year were 30.0% (95% CI, 14.7–46.9%) in the allogeneic SCT and 0% in the autologous SCT group. The estimated 3-year overall (OS) and progression-free (PFS) survival rates were 84.5% (95% CI, 66.0–93.4%) and 70.8% (95% CI, 53.0–82.9%) in the autologous SCT group, and 52.2% (95% CI, 32.5–68.6%) and 45.0% (95% CI, 26.3–62.0%) in the allogeneic SCT group. No patients died after the first 2 years following allogeneic SCT. In univariate analyses, disease status at SCT was significantly associated with PFS in autologous SCT, and with OS and PFS in allogeneic SCT. These results suggest that both autologous and allogeneic SCT have each potential role in WM. Allogeneic SCT is more curative for WM, but is associated with high NRM.
AB - The role of stem cell transplantation (SCT) for patients with Waldenström’s macroglobulinemia (WM) remains undetermined. Therefore, we retrospectively evaluated the outcome of autologous and allogeneic SCT for patients with WM using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-six patients receiving autologous and 31 receiving allogeneic SCT were analyzed. The allogeneic SCT group included more patients with advanced disease status at transplant and received more lines of chemotherapy. The cumulative incidences of non-relapse mortality (NRM) at 1 year were 30.0% (95% CI, 14.7–46.9%) in the allogeneic SCT and 0% in the autologous SCT group. The estimated 3-year overall (OS) and progression-free (PFS) survival rates were 84.5% (95% CI, 66.0–93.4%) and 70.8% (95% CI, 53.0–82.9%) in the autologous SCT group, and 52.2% (95% CI, 32.5–68.6%) and 45.0% (95% CI, 26.3–62.0%) in the allogeneic SCT group. No patients died after the first 2 years following allogeneic SCT. In univariate analyses, disease status at SCT was significantly associated with PFS in autologous SCT, and with OS and PFS in allogeneic SCT. These results suggest that both autologous and allogeneic SCT have each potential role in WM. Allogeneic SCT is more curative for WM, but is associated with high NRM.
UR - http://www.scopus.com/inward/record.url?scp=85085001993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085001993&partnerID=8YFLogxK
U2 - 10.1007/s00277-020-04078-3
DO - 10.1007/s00277-020-04078-3
M3 - Article
C2 - 32424672
AN - SCOPUS:85085001993
SN - 0939-5555
VL - 99
SP - 1635
EP - 1642
JO - Annals of Hematology
JF - Annals of Hematology
IS - 7
ER -